KORELASI KADAR C-REACTIVE PROTEIN DENGAN JUMLAH TROMBOSIT PADA PENDERITA DIABETES MELITUS TIPE 2
Main Article Content
Abstract
Type 2 diabetes mellitus (DM) is a chronic metabolic disorder characterized by hyperglycemia and insulin resistance, associated with decreased nitric oxide (NO) levels, increased free radical production, inflammation, endothelial dysfunction, and progressive vascular damage. C-reactive protein (CRP), an acute phase protein regulated by pro-inflammatory cytokines like interleukin-6 (IL-6), serves as a systemic inflammation marker. Pentameric CRP (pCRP) and monomeric CRP (mCRP) are implicated in mediating inflammation and endothelial dysfunction, with roles in endothelial cell adhesion, phagocytosis, inflammatory signaling, and interactions with endothelial cells, neutrophils, macrophages, and platelets. Additionally, leukocytes secrete platelet-activating factors, enhancing platelet activation and cytokine and chemokine release. This descriptive analytical study with a cross-sectional design aimed to investigate the correlation between CRP levels and platelet counts in patients with type 2 DM. Utilizing purposive sampling, 47 patients diagnosed with DM at Sultan Syarif Mohamad Alkadrie Hospital, Pontianak, during June 2023 were selected. CRP levels were measured using the fluorescence immunoassay (FIA) method, while platelet counts were determined through the impedance method. Statistical analysis employing Kendall's Tau-b test revealed a significant correlation (p < 0.05, r = -0.508), indicating that elevated CRP levels are significantly associated with reduced platelet counts in type 2 DM patients.
Article Details
References
GBD 2021 Diabetes Collaborators, “Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021,” Lancet, vol. 402, no. 10397, p. 203—234, Jul. 2023, doi: 10.1016/s0140-6736(23)01301-6.
U. Galicia-Garcia et al., “Pathophysiology of Type 2 Diabetes Mellitus,” Int J Mol Sci, vol. 21, no. 17, p. E6275, Aug. 2020, doi: 10.3390/ijms21176275.
C.-X. Ma, X.-N. Ma, C.-H. Guan, Y.-D. Li, D. Mauricio, and S.-B. Fu, “Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management,” Cardiovasc Diabetol, vol. 21, no. 1, p. 74, May 2022, doi: 10.1186/s12933-022-01516-6.
G. W. Katulanda et al., “Plasma glucose in screening for diabetes and pre-diabetes: how much is too much? Analysis of fasting plasma glucose and oral glucose tolerance test in Sri Lankans,” BMC Endocr Disord, vol. 19, no. 1, p. 11, Jan. 2019, doi: 10.1186/s12902-019-0343-x.
J. Stanimirovic et al., “Role of C-Reactive Protein in Diabetic Inflammation,” Mediators Inflamm, vol. 2022, p. 3706508, 2022, doi: 10.1155/2022/3706508.
N. A. Abdul Murad et al., “Discordance between Fasting Plasma Glucose (FPG) and HbA1c in Diagnosing Diabetes and Pre-diabetes in The Malaysian Cohort,” J ASEAN Fed Endocr Soc, vol. 36, no. 2, p. 127—132, 2021, doi: 10.15605/jafes.036.02.02.
A. Basit et al., “Glycated hemoglobin (HbA1c) as diagnostic criteria for diabetes: the optimal cut-off points values for the Pakistani population; a study from second National Diabetes Survey of Pakistan (NDSP) 2016-2017,” BMJ open diabetes research & care, vol. 8, no. 1, p. e001058, May 2020, doi: 10.1136/bmjdrc-2019-001058.
M. F. Figueira et al., “MicroRNAs: potential therapeutic targets in diabetic complications of the cardiovascular and renal systems,” Acta Physiol (Oxf), vol. 211, no. 3, pp. 491–500, 2014, doi: 10.1111/apha.12316.
C. Iacobini, M. Vitale, C. Pesce, G. Pugliese, and S. Menini, “Diabetic Complications and Oxidative Stress: A 20-Year Voyage Back in Time and Back to the Future,” Antioxidants (Basel), vol. 10, no. 5, p. 727, May 2021, doi: 10.3390/antiox10050727.
F. Liu, C. Liu, I. X. Y. Lee, M. T. Y. Lin, and Y.-C. Liu, “Corneal dendritic cells in diabetes mellitus: A narrative review,” Front Endocrinol (Lausanne), vol. 14, p. 1078660, 2023, doi: 10.3389/fendo.2023.1078660.
S. K. Sah et al., “A contemporary biological pathway of islet amyloid polypeptide for the management of diabetic dementia,” Chem Biol Interact, vol. 306, p. 117—122, Jun. 2019, doi: 10.1016/j.cbi.2019.04.022.
S. Cernea and I. Raz, “Management of diabetic neuropathy,” Metabolism, vol. 123, p. 154867, Oct. 2021, doi: 10.1016/j.metabol.2021.154867.
M. A. Hill et al., “Insulin resistance, cardiovascular stiffening and cardiovascular disease,” Metabolism, vol. 119, p. 154766, Jun. 2021, doi: 10.1016/j.metabol.2021.154766.
D. J. Medina-Leyte, O. Zepeda-García, M. Domínguez-Pérez, A. González-Garrido, T. Villarreal-Molina, and L. Jacobo-Albavera, “Endothelial Dysfunction, Inflammation and Coronary Artery Disease: Potential Biomarkers and Promising Therapeutical Approaches,” Int J Mol Sci, vol. 22, no. 8, p. 3850, Apr. 2021, doi: 10.3390/ijms22083850.
A. I. S. Sobczak and A. J. Stewart, “Coagulatory Defects in Type-1 and Type-2 Diabetes,” Int J Mol Sci, vol. 20, no. 24, p. E6345, Dec. 2019, doi: 10.3390/ijms20246345.
Perkeni, Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia. Jakarta: PB PERKENI, 2019. [Online]. Available: https://pbperkeni.or.id/wp-content/uploads/2021/06/Pedoman-Pengelolaan-DM-Tipe-2-Dewasa-di-Indonesia-eBook-PDF.pdf
M. Y. Donath, D. T. Meier, and M. Böni-Schnetzler, “Inflammation in the Pathophysiology and Therapy of Cardiometabolic Disease,” Endocr Rev, vol. 40, no. 4, p. 1080—1091, Aug. 2019, doi: 10.1210/er.2019-00002.
E. Hasheminasabgorji and J. C. Jha, “Dyslipidemia, Diabetes and Atherosclerosis: Role of Inflammation and ROS-Redox-Sensitive Factors,” Biomedicines, vol. 9, no. 11, p. 1602, Nov. 2021, doi: 10.3390/biomedicines9111602.
K. Stark and S. Massberg, “Interplay between inflammation and thrombosis in cardiovascular pathology,” Nat Rev Cardiol, vol. 18, no. 9, p. 666—682, Sep. 2021, doi: 10.1038/s41569-021-00552-1.
L. Wang and C. Tang, “Targeting Platelet in Atherosclerosis Plaque Formation: Current Knowledge and Future Perspectives,” Int J Mol Sci, vol. 21, no. 24, p. E9760, Dec. 2020, doi: 10.3390/ijms21249760.
F. Santilli, P. Simeone, R. Liani, and G. Davì, “Platelets and diabetes mellitus,” Prostaglandins & other lipid mediators, vol. 120, pp. 28–39, 2015, doi: 10.1016/j.prostaglandins.2015.05.002.
L. V Nedosugova et al., “Inflammatory Mechanisms of Diabetes and Its Vascular Complications,” Biomedicines, vol. 10, no. 5, p. 1168, May 2022, doi: 10.3390/biomedicines10051168.
S. Tsalamandris et al., “The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives,” Eur Cardiol, vol. 14, no. 1, p. 50—59, Apr. 2019, doi: 10.15420/ecr.2018.33.1.
T. V Rohm, D. T. Meier, J. M. Olefsky, and M. Y. Donath, “Inflammation in obesity, diabetes, and related disorders,” Immunity, vol. 55, no. 1, p. 31—55, Jan. 2022, doi: 10.1016/j.immuni.2021.12.013.
A. Berbudi, N. Rahmadika, A. I. Tjahjadi, and R. Ruslami, “Type 2 Diabetes and its Impact on the Immune System,” Curr Diabetes Rev, vol. 16, no. 5, p. 442—449, 2020, doi: 10.2174/1573399815666191024085838.
H. Zhang et al., “Sex-Based Differences in Diabetes Prevalence and Risk Factors: A Population-Based Cross-Sectional Study Among Low-Income Adults in China,” Front Endocrinol (Lausanne), vol. 10, p. 658, 2019, doi: 10.3389/fendo.2019.00658.
E. Eyth and R. Naik, Hemoglobin A1C. Treasure Island: StatPearls Publishing, Treasure Island (FL), 2023. [Online]. Available: http://europepmc.org/books/NBK549816
A. A. Lintang S, H. Mutiara, and R. Falamy, “Hubungan Antara Lama Menderita Diabetes Melitus Tipe 2 Dengan Kejadian Peripheral Arterial Disease Pada Pasien Diabetes Melitus Tipe 2 Di Puskesmas Kedaton Kota Bandar Lampung,” MEDULA, medicalprofession journal of lampung university, vol. 9, no. 2, pp. 379–384, 2019.
N. W. Haryono, D. Gunawan, and P. N. Kembaren, “Hubungan Lama Menderita Diabetes Melitus Dengan Derajat Sindrom Mata Kering Pada Penderita Diabetes Melitus Tipe 2 Di Rumah Sakit Badan Pengusahaan Batam,” Zona Kedokteran: Program Studi Pendidikan Dokter Universitas Batam, vol. 13, no. 1, pp. 275–282, 2023.
E. Juwita, S. Susilowati, N. E. Mauliku, and D. K. Nugrahaeni, “Faktor Yang Berhubungan Dengan Kadar Gula Darah Pada Penderita Diabetes Melitus Tipe 2 Di Prolanis Puskesmas Kecamatan Cimahi Tengah,” Journal of Nutrition College, vol. 9, no. 2, pp. 87–93, 2020.
S. Rachmawati and M. Sulchan, “Asupan Lemak Dan Kadar High Density Lipoprotein (HDL) Sebagai Faktor Risiko Peningkatan Kadar C-Reactive Protein (CRP) pada Remaja Obesitas dengan Sindrom Metabolik,” Journal of Nutrition College, vol. 3, no. 3, pp. 337–345, Feb. 2014, doi: 10.14710/jnc.v3i3.6586.
E. Svensson et al., “Lifestyle and clinical factors associated with elevated C-reactive protein among newly diagnosed Type 2 diabetes mellitus patients: a cross-sectional study from the nationwide DD2 cohort,” BMC Endocr Disord, vol. 14, p. 74, Aug. 2014, doi: 10.1186/1472-6823-14-74.
S. Rohe, E. Röhner, C. Windisch, G. Matziolis, S. Brodt, and S. Böhle, “Sex Differences in Serum C-Reactive Protein Course after Total Hip Arthroplasty,” Clin Orthop Surg, vol. 14, no. 1, p. 48—55, Mar. 2022, doi: 10.4055/cios21110.
M. Ranucci et al., “Gender-based differences in platelet function and platelet reactivity to P2Y12 inhibitors,” PLoS One, vol. 14, no. 11, p. e0225771, 2019, doi: 10.1371/journal.pone.0225771.
S. R, G. K. Saharia, S. Patra, D. Bandyopadhyay, and B. K. Patro, “Flow cytometry based platelet activation markers and state of inflammation among subjects with type 2 diabetes with and without depression,” Sci Rep, vol. 12, no. 1, p. 10039, Jun. 2022, doi: 10.1038/s41598-022-13037-z.
S. A. Rizo-Téllez, M. Sekheri, and J. G. Filep, “C-reactive protein: a target for therapy to reduce inflammation,” Front Immunol, vol. 14, p. 1237729, 2023, doi: 10.3389/fimmu.2023.1237729.
V. Caprio et al., “pCRP-mCRP Dissociation Mechanisms as Potential Targets for the Development of Small-Molecule Anti-Inflammatory Chemotherapeutics,” Front Immunol, vol. 9, p. 1089, 2018, doi: 10.3389/fimmu.2018.01089.
X. Li et al., “Effects of Hyperglycemia and Diabetes Mellitus on Coagulation and Hemostasis,” J Clin Med, vol. 10, no. 11, p. 2419, May 2021, doi: 10.3390/jcm10112419.
R. Kaur, M. Kaur, and J. Singh, “Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies,” Cardiovasc Diabetol, vol. 17, no. 1, p. 121, Aug. 2018, doi: 10.1186/s12933-018-0763-3.
R. Renowati and R. Sefridana, “Korelasi C-Reactive Protein Dengan Trombosit Pada Penderita Demam Berdarah Dengue,” in Prosiding Seminar Kesehatan Perintis, 2020, p. 8.
L. Badimon et al., “C-Reactive Protein in Atherothrombosis and Angiogenesis,” Front Immunol, vol. 9, p. 430, 2018, doi: 10.3389/fimmu.2018.00430.
Y. Zeinolabediny, S. Kumar, and M. Slevin, “Monomeric C-Reactive Protein - A Feature of Inflammatory Disease Associated With Cardiovascular Pathophysiological Complications?,” In Vivo, vol. 35, no. 2, p. 693—697, 2021, doi: 10.21873/invivo.12309.